Lamb, Harriet M.; Goa, Karen L. - In: Disease Management and Health Outcomes 5 (1999) 2, pp. 101-115
/day consistently demonstrated similar efficacy to other regimens (imipenem/ cilastatin, ceftazidime with or without amikacin) commonly …, with possibly fewer gastrointestinal and CNS tolerability problems than imipenem/cilastatin. Therefore, meropenem is likely …